Roche’s Genentech Gets Green Light for Vixarelimab UC Clinical Trial in China
Roche (SWX: ROG)’s Genentech, a leading biotechnology company based in Switzerland, has received approval to...
Clinical trial approval / initiation
NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment
NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...
Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced that it...
Changchun High & New Technology Industries Gets Green Light for Jinnamab Clinical Trial
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company based...
Sichuan Biokin’s BL-B01D1 Advances to Phase III for HR+/HER2- Breast Cancer
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced the enrollment...
Alphamab Oncology’s JSKN016 Begins Phase I Clinical Trial for Solid Tumor Treatment
Alphamab Oncology (HKG: 9966), a biopharmaceutical company, has announced that the first patient has been...
Jiangsu Hengrui’s SHR1905 Anti-TSLP mAb Gets Green Light for COPD Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it...
ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...
Bayer’s 225Ac-PSMA-Trillium Therapy Begins Early-Stage Clinical Trial for mCRPC
Bayer AG (ETR: BAYN), a multinational pharmaceutical company based in Germany, has this week commenced...
Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer
China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...
Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...
Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors
China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...
Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...
RemeGen’s Telitacicept Achieves Full Enrollment in Phase III Primary Sjogren’s Syndrome Trial
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the completion of patient enrollment in a...
Roche and Genprex Initiate Phase I Trial Combining Tecentriq and Reqorsa for ES-SCLC
Switzerland-based Roche (SWX: ROG) is advancing the evaluation of its anti-PD-L1 drug, Tecentriq (atezolizumab), in...
HutchMed’s HMPL-306 Advances to Phase III Trial in R/R AML Patients
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced the commencement of the RAPHAEL study,...
Yunnan Baiyao’s Radiopharmaceutical INR101 Advances to Clinical Trial Stage with NMPA Approval
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...
Jacobio Pharma’s KRAS G12C Inhibitor Gains NMPA Approval for Phase III CRC Study
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced that it has...